Caloric restriction normalizes bile acid, cholesterol deficiency

March 20, 2017

(HealthDay)—Acute caloric restriction normalizes hepatic bile acid (BA) and cholesterol deficiency that is seen in morbidly obese women, according to a study published online March 6 in the Journal of Internal Medicine.

Sara Straniero, Ph.D., from Karolinska University Hospital in Stockholm, and colleagues monitored 10 morbidly obese women on days zero, three, seven, 14, and 28 after initiating a low-calorie diet. They collected serum and determined liver size and fat content. The results were compared with those from 54 non-obese women who served as controls.

The researchers found that, compared with controls, the obese group had elevated synthesis of both BAs and cholesterol and of BAs and proprotein convertase subtilisin/kexin type 9 (PCSK9) at baseline. BA and cholesterol synthesis and serum BA and PCSK9 levels normalized after three days on the low-calorie diet, while increased. There was no change in fibroblast growth factor 19 and triglyceride levels, and a 10 percent decrease was seen in liver volume.

"The results suggest that hepatic BAs and cholesterol are deficient in morbid obesity," the authors write. "Caloric restriction rapidly counteracts these deficiencies, normalizing BA and and circulating PCSK9 levels, indicating that overproduction of in enlarged peripheral tissues cannot explain this phenotype."

Explore further: New lipid-lowering drugs help patients reduce LDL cholesterol

More information: Abstract
Full Text

Related Stories

New lipid-lowering drugs help patients reduce LDL cholesterol

August 1, 2016
A recent analysis indicates that adding new therapies called anti-PCSK9 antibodies to other lipid-lowering treatments can help patients lower their LDL cholesterol levels.

PCSK9 monoclonal antibodies show promise in ACS

March 23, 2016
(HealthDay)—Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies may represent a promising treatment option for acute coronary syndrome (ACS), according to a review published online March 22 in the ...

US regulators give limited approval to cholesterol drug

July 25, 2015
US regulators on Friday approved a new cholesterol drug called Praluent, made by Sanofi and Regeneron, for people with certain genetic risk factors for heart disease.

Greater drop in LDL seen with atorvastatin plus PCSK9 antibody

November 2, 2012
(HealthDay)—Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated with greater reductions in low-density lipoprotein (LDL) cholesterol levels ...

PCSK9 inhibitors reduce lipoprotein (a) production

October 31, 2016
A new study published today in JACC: Basic to Translational Science sheds light on PCSK9 inhibitors, a new class of low density lipoprotein (LDL) lowering drugs, and their impact on another risk factor for heart disease, ...

Risk of cardiovascular disease and diabetes affected by PCSK9 and HMGCR genetic variations

November 30, 2016
In a new study published in the December 1, 2016 issue of The New England Journal of Medicine (NEJM), researchers at Brigham and Women's Hospital, and a collaboration of international researchers, studied variants in the ...

Recommended for you

No sweat required: Team finds hypertension treatment that mimics effect of exercise

October 16, 2018
Couch potatoes rejoice—there might be a way to get the blood pressure lowering benefits of exercise in pill form.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Why heart contractions are weaker in those with hypertrophic cardiomyopathy

October 16, 2018
When a young athlete suddenly dies of a heart attack, chances are high that they suffer from familial hypertrophic cardiomyopathy (HCM). Itis the most common genetic heart disease in the US and affects an estimated 1 in 500 ...

Novel genetic study sheds new light on risk of heart attack

October 12, 2018
Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.

Researchers say ritual for orthodox Jewish men may offer heart benefits

October 11, 2018
A pilot study led by researchers at the University of Cincinnati (UC) College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily ...

Markers of dairy fat consumption linked to lower risk of type two diabetes

October 10, 2018
Higher levels of biomarkers of dairy fat consumption are associated with a lower risk of developing type 2 diabetes, according to new research published today in PLOS Medicine. The study, in more than 60,000 adults, was undertaken ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.